TikTok Star Brianna 'Chickenfry' LaPaglia Issues Stark Warning Over Trendy GLP-1 Drug Use
Brianna 'Chickenfry' LaPaglia, the 26-year-old TikTok sensation with 3.6 million social media followers, has launched a scathing critique against the rampant use of trendy GLP-1 agonist drugs like Ozempic. She specifically targeted non-diabetic skinny women who microdose these medications for weight loss purposes.
'No tea, no shade, no hate, just some field research,' LaPaglia declared on Tuesday. 'Every single bi*** I know is on Ozempic. People that do not need Ozempic. It's like if I did Ozempic. Could I lose a couple? Surely. Do I need Ozempic? No!'
The Special Forces contestant concluded with an ominous warning: 'You're gonna die. You're all gonna die!'
FDA Issues Serious Warning to Novo Nordisk
LaPaglia's comments come just one week after the Food and Drug Administration (FDA) issued a stern warning to pharmaceutical giant Novo Nordisk over 'serious violations' involving failure to report adverse side effects in GLP-1 patients, including deaths.
The FDA's March 5 letter specifically listed three unreported deaths among patients using semaglutide, including one suicide case, along with a patient who suffered a stroke while taking liraglutide.
Novo Nordisk now has 15 days to outline additional corrective measures or potentially face regulatory action. The company responded on Tuesday that they have already implemented a 'corrective and preventative action plan.'
Alarming Statistics and Potential Health Risks
According to recent reports, the FDA's Adverse Event Reporting System received concerning data between 2022 and 2023:
- 49 death reports for tirzepatide
- 34 life-threatening reports
- 24 disability reports
Medical experts warn that GLP-1 patients could potentially die from serious complications including:
- Gastroparesis (stomach paralysis)
- Gallbladder problems
- Kidney failure
- Pancreatitis
- Thyroid cancer
Lisa Marie Presley Case and Medical Concerns
The discussion around GLP-1 risks gained particular attention in 2023 following the tragic death of Lisa Marie Presley at age 54 from 'small bowel obstruction' resulting from bariatric surgery years earlier.
Dr. Terry Dubrow, a 67-year-old plastic surgeon, speculated to TMZ that Presley might have been taking a GLP-1 drug. 'Recent studies have shown that if you're on Ozempic-type drugs, they can slow down your intestines. They can predispose you to intestinal obstruction,' he explained.
'And there may be the perfect unfortunate storm of previous surgery with intestinal scarring, opioid use, where you can’t tell that you're that sick, and further slowing of the intestines by the use of these miracle weight loss drugs.'
Celebrity Usage and Regulatory Context
The FDA has only approved three GLP-1 drugs specifically for weight loss: Wegovy (semaglutide), Saxenda (liraglutide), and Zepbound (tirzepatide). All others remain specifically indicated for patients suffering from type 2 diabetes.
Despite this, numerous celebrities have publicly admitted to using these diabetic injectables for weight management, including:
- Oprah Winfrey
- Kathy Bates
- Whoopi Goldberg
- Kelly Clarkson
- Elon Musk
- Rebel Wilson
- Sharon Osbourne
Many other high-profile figures have remained suspiciously silent about their weight loss while speculation continues about potential GLP-1 use, including Mindy Kaling, Selena Gomez, Khloé Kardashian, and Demi Lovato.
Contrasting Research Findings
In a surprising counterpoint, a BMJ study released on March 4 examined 606,434 US veterans and suggested that GLP-1 drugs might actually help reduce addiction risks to substances including alcohol, cannabis, cocaine, nicotine, and opioids, potentially preventing overdose deaths.
This creates a complex medical landscape where these medications show both significant risks and potential benefits, highlighting the importance of proper medical supervision and adherence to approved usage guidelines.
